RE:RE:RE:RE:920 K 920 K 920 Freaking Thousand "Even if they 'high jack' macropheds it's 7 to 10 years to get it in marketable product form and then the same time line to confirm how the receptors behave - can be some overlap of course"
Are you saying that a licensing deal would add no value to this stock at $.25?
CoQ10 is an approved product. Yeast beta glucan is a billion dollar estabilished market. CZO combines two approved commonly used products. PGX leaves the yeast beta glucan in a more natural state. CZO has produced blowout CoQ10 bioavailability results against the industry gold standard in an animal model and this may be because it can hijack macrophages by getting inside of them. CZO's PGX-YBG is also 5X more immune stimulatory than spray dried products in one study and CZO has now designed an animal study for a further head-to-head study. Gilles said CoQ10 is a $4 billion market. Yeast beta glucan is a $1 billion market in the much larger immune booster market. Gilles said at the AGM that it is in talks with serious companies who understand the importance of bioavailability. CZO is scaling up PGX to commercial scale right now. The 5X scale-up facility is expected to be completed by the end of the year with commissioning in Q1 and the 10X facility is expected to be built in September with commissioning to follow. 50% of the equipment and infrastructure is believed already in place. In the past CZO has talked about a potential simultaneous PGX deal with a NASDAQ listing. What would the value of this be to CZO upon successfuly 5X, 10X scale-up to commercial scale and a licensing deal for CoQ10 with a pharma or neutraceutical company. Is it worth more than zero? How much more. Do you think CZO is trying to get on NASDAQ because it sees no value in what is about t happen? CZO could also extend applications of its potential Trojan Horse to other drugs.
Tencents wrote: Even if they 'high jack' macropheds it's 7 to 10 years to get it in marketable product form
and then the same time line to confirm how the receptors behave - can be some overlap of course
no matter how we look at it the timelines are 2035 to 2040 and that's assuming any of this goes the distance
seems like far too many projets on hand - a narrow focus with faster progress needs warranting